Autosomal dominant cerebellar ataxias (ADCAs) share features of progressive, usually adult-onset, spinocerebellar degeneration, including gait and limb ataxia, dysarthria, and oculomotor control impairment. The presence of peripheral nerve involvement in ADCAs has been reported, suggesting that disease mechanisms are not solely confined to the central nervous system compartment. In a large study, covering twenty-seven genotyped ADCA patients electrophysiological evidence of involvement of the peripheral nervous system was found in 70% of patients. Findings were compatible with a dying-back axonopathy in 30%, while in 40% of patients a neuronopathy was diagnosed. SCA1 and SCA2 patients mostly displayed features of a neuronopathy, while in SCA3 and SCA7 both neuronopathies and axonopathies were encountered. In SCA6, no significant peripheral nerve involvement was demonstrated.
H.J. Schelhaas, M.D., Ph.D.
B.P. van de Warrenburg, M.D., Ph.D.
Van de Warrenburg et al did not find any correlation between the sum of CMAPs/SNAPs and age, disease duration, or ataxia severity. Previously, the severity of the axonal polyneuropathy in SCA3 patients was found to be related to age and not to CAG repeat length or disease duration.4 SCA2 patients with a later age-at-onset (> 40 years) and small CAG repeat expansions, both suggesting milder disease, were found to display a more severe peripheral neuropathy.20 Van alfen et al. recently reported a SCA3 family, carrying intermediate repeat expansions, with a syndrome encompassing restless legs, fasciculations, and a sensorimotor axonal polyneuropathy.21 Apparently, peripheral nerve involvement, both neuronopathies and axonopathies, can be an early disease feature, can occur in patients with relatively small repeat expansions, and is not related to disease progression. Whether the neuropathy in the individual patient with SCA is stable or slowly progressive is currently unknown.
International prevalence estimates of autosomal dominant cerebellar ataxias (ADCA) vary from 0.3 to 2.0 per 100,000. The estimated minimal prevalence of ADCA in the Netherlands is 3.0 per 100,000 inhabitants.1
DNA analysis, nerve conduction studies, and EMG. Further ancillary investigations depends on the differential diagnostic considerations.
Therapy is symptomatic and supportive.